The Danger of Smoking and E-cigarettes in Brazil

Sep.02.2022
The Danger of Smoking and E-cigarettes in Brazil
Smoking is the primary cause of lung cancer in Brazil's Mato Grosso state, with e-cigarettes becoming a popular and dangerous alternative.

In the state of Mato Grosso do Sul in Brazil, there are 15.6 cases of tracheal, bronchial, and lung cancer per 100,000 males and 7.9 cases per 100,000 females, with similar ratios. According to data from the US National Cancer Institute (INCA), these types of tumors are primarily caused by smoking.


Smoking is the second leading cause of cancer in men, with only prostate cancer having a higher incidence rate. In women, it is the third leading cause, following breast and cervical cancer.


Giovanna Figaredo, a pulmonologist who works at the St. Matthew's Hospital in Cubatão, believes that in addition to traditional smoking methods such as cigarettes, cigars, and pipes, electronic cigarettes are becoming a popular and harmful trend, especially among young people.


Many individuals believe that electronic cigarettes are "healthier," but this is a myth. We must uncover the mysterious veil of this information in order to guide people away from consumption. Electronic cigarettes are banned in Brazil because they are unsafe. Many people are even unaware of what they are inhaling, the doctor explained.


This pulmonologist has warned that smoking increases the risk of more than 20 types of cancers, in addition to the most common ones such as lung cancer, bronchial cancer, and tracheal cancer. Furthermore, smoking also increases the risk of cardiovascular diseases such as heart disease and stroke. It can lead to pulmonary diseases like chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and decreased fertility.


In regards to e-cigarettes, the long-term damage of their use is still largely unknown due to the higher consumption rates of this generation. However, there have been cases of patients with deteriorating lung conditions such as asthma. Additionally, there is EVALI (electronic cigarette or vaping product use-associated lung injury), which is an acute lung disease associated with the use of e-cigarettes," he pointed out.


Nicotine is a disease.


Doctor Giovanna Figueiredo explained that nicotine addiction is considered a disease and is classified under the International Classification of Diseases (ICD). It can lead to physical and psychological dependency.


Experts emphasize that the first step to overcoming the difficulties of quitting smoking is willpower and determination. "I usually guide people to make changes in their daily habits, such as changing the place where they usually keep their cigarettes, delaying the first cigarette of the day as much as possible, and avoiding drinks that encourage smoking, such as coffee and alcoholic beverages. After making these changes, it is important to set a date to permanently quit tobacco use.


Doctors emphasize that certain medications can assist with quitting smoking and also help control withdrawal symptoms and anxiety. They point out that seeking professional help for guidance, planning, and medication prescriptions is crucial when needed.


Statement:


This article is compiled from third-party information and is only intended for industry-related exchange and learning.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry-related communication and research purposes.


Due to limitations in the translator's ability, translated articles may not accurately reflect the original text. It is recommended to refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania begins enforcing its electronic nicotine delivery system (ENDS) directory restrictions on October 19, 2026. The October 18 directory contained 163 product records from seven manufacturers, including Vuse, JUUL, NJOY, Logic and Naked 100. Geek Bar, RAZ and Lost Mary were absent. BAT, Altria, Japan Tobacco and JUUL collectively accounted for 112 records, or 68.7%, while Imperial Brands' blu had no listings. The directory included 15 disposable vape records, 40 bottled e-liquids and 10 products labeled 0mg, but no open-system refillable devices. Twenty-two manufacturer certifications remained under review. Four Logic models corresponding to Smoore's pending records were listed under the brand owner, while LYCO, OXBAR and Boulder/Rock had no approved directory entries.
Regulations
Oct.19
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06